Zosurabalpin
Clinical data
Other namesN2.2.2.1,3-anhydro(N2-[(2-([2-(aminomethyl)-4'-carboxy[1,1'-biphenyl]-3-yl]sulfanyl)pyridin-3-yl)methyl]-L-ornithyl-L-lysyl-N-methyl-L-tryptophan
Identifiers
  • 4-[(11S,14S,17S)-14-(4-aminobutyl)-11-(3-aminopropyl)-17-(1H-indol-3-ylmethyl)-16-methyl-12,15,18-trioxo-2-thia-4,10,13,16,19-pentazatricyclo[19.4.0.03,8]pentacosa-1(25),3(8),4,6,21,23-hexaen-22-yl]benzoic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC43H50N8O5S
Molar mass790.98 g·mol−1
3D model (JSmol)
  • CN1[C@H](C(=O)NCC2=C(C=CC=C2SC3=C(CN[C@H](C(=O)N[C@H](C1=O)CCCCN)CCCN)C=CC=N3)C4=CC=C(C=C4)C(=O)O)CC5=CNC6=CC=CC=C65
  • InChI=1S/C43H50N8O5S/c1-51-37(23-30-25-47-34-12-3-2-10-32(30)34)40(53)49-26-33-31(27-16-18-28(19-17-27)43(55)56)11-6-15-38(33)57-41-29(9-8-22-46-41)24-48-35(14-7-21-45)39(52)50-36(42(51)54)13-4-5-20-44/h2-3,6,8-12,15-19,22,25,35-37,47-48H,4-5,7,13-14,20-21,23-24,26,44-45H2,1H3,(H,49,53)(H,50,52)(H,55,56)/t35-,36-,37-/m0/s1
  • Key:NJFUXFYUHIHHOJ-FSEITFBQSA-N

Zosurabalpin (RG6006, Abx-MCP, Ro7223280) is an experimental antibiotic developed in a collaboration between the pharmaceutical company Roche and scientists from Harvard University, for the treatment of carbapenem-resistant Acinetobacter baumannii (CRAB). It targets a lipopolysaccharide transporter.[1] It works by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate.[2] The chemical family to which it belongs was first disclosed in 2019, but the particular structure of RG6006 remained confidential until publication of the testing results in 2023.[3][4][5]

See also

References

  1. ↑ Zampaloni C, Mattei P, Bleicher K, Winther L, Thäte C, Bucher C, et al. (January 2024). "A novel antibiotic class targeting the lipopolysaccharide transporter". Nature. doi:10.1038/s41586-023-06873-0. PMID 38172634.
  2. ↑ Pahil KS, Gilman MS, Baidin V, Clairfeuille T, Mattei P, Bieniossek C, et al. (January 2024). "A new antibiotic traps lipopolysaccharide in its intermembrane transporter". Nature: 1–6. doi:10.1038/s41586-023-06799-7. PMID 38172635.
  3. ↑ US 20190321440A1, Bleicher K, Cheang D, Di Giorgio P, Hu T, Jenny C, Mattei P, Schmitz P, Stoll T, "Peptide macrocycles against acinetobacter baumannii.", issued 21 November 2023, assigned to Hoffmann La Roche Inc.
  4. ↑ Erbetti I, Ferrari L, Ortombina A, Savoia P, Felici A, Bissantz C, Zampaloni C (December 2023). "2109. In vitro and in vivo Killing Kinetics of Zosurabalpin (RG6006) Against Acinetobacter baumannii.". Open Forum Infectious Diseases. Vol. 10. Oxford University Press. doi:10.1093/ofid/ofad500.1733.
  5. ↑ Theuretzbacher U (October 2023). "Evaluating the innovative potential of the global antibacterial pipeline". Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. doi:10.1016/j.cmi.2023.09.024. PMID 37805036. S2CID 263722286.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.